Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» PharmaMar
PharmaMar
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
Cancer drug derived from sea squirts outperforms remdesivir in COVID-19 preclinical models
Fierce Biotech
Wed, 01/27/21 - 11:22 am
PharmaMar
plitidepsin
Aplidin
remdesivir
COVID-19
Jazz Pharma’s $1B bet pays off with accelerated lung cancer approval
Endpoints
Tue, 06/16/20 - 10:37 am
Jazz Pharma
PharmaMar
FDA
Zepzelca
lurbinectedin
small cell lung cancer
Jazz targets US launch of SCLC drug after FDA grants fast review
Pharmaforum
Mon, 02/17/20 - 10:21 am
PharmaMar
Jazz Pharmaceuticals
FDA
small cell lung cancer
lurbinectedin
priority review
Jazz rolls the dice on a billion-dollar gamble on a new drug for SCLC — shooting for a 2020 launch
Endpoints
Thu, 12/19/19 - 12:53 pm
Jazz Pharma
lurbinectedin
SCLC
PharmaMar
PharmaMar files for FDA approval of small cell lung cancer drug
Fierce Biotech
Tue, 12/17/19 - 10:37 am
PharmaMar
FDA
lurbinectedin
small cell lung cancer
Zepsyre has a path to market at last
EP Vantage
Mon, 08/19/19 - 10:55 am
PharmaMar
FDA
Zepsyre
small cell lung cancer
After ovarian cancer flop, PharmaMar's lurbinectedin makes the cut in small cell lung cancer
Endpoints
Mon, 03/25/19 - 10:19 am
PharmaMar
ovarian cancer
lurbinectedin
relapsed small cell lung cancer
small cell lung cancer
Sylentis' dry eye drug misses primary goals in phase 3
Fierce Biotech
Thu, 01/31/19 - 11:55 pm
Sylentis
dry eye disease
PharmaMar
siRNA
tivanisiran
clinical trials
3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News
GoinPharma
Sun, 03/25/18 - 11:24 am
biotech
FDA
Azedra
Progenics Pharmaceuticals
AbbVie
Rova-T
PharmaMar
PharmaMar stock tanks after PhIII ovarian cancer study flops
Endpoints
Sat, 01/20/18 - 02:53 pm
PharmaMar
ovarian cancer
clinical trials
Zepsyre
20,000 leagues for biotech to explore
BioPharma Dive
Mon, 03/27/17 - 10:31 am
biotech
bioprospecting
PharmaMar
BeyondSpring
Ohr Pharmaceutical
Wex Pharmaceuticals